[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![MoHossain Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::22736189.png) Mo Hossain [@MoHossain](/creator/twitter/MoHossain) on x 6305 followers
Created: 2025-06-04 02:10:44 UTC

In a market challenged by high interest rates and policy uncertainty, two major deals are reinvigorating biotech M&A. Sanofi will acquire Blueprint Medicines for $XXX billion (up to $XXX billion with milestones), while Bristol-Myers Squibb is set to pay BioNTech $XXX billion for a XX% stake in an immunotherapy candidate—potentially rising to $XXXX billion. These transactions, which offer significant valuation premiums and target innovative treatments in immuno-oncology, demonstrate that even in tough times, strategic capital flows can unlock substantial value. 
⬇️
Biotech M&A shows signs of life

#Lifescience #healthcare #investor #

![](https://pbs.twimg.com/media/GskJ355WIAAwHH6.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1930084774389186905/c:line.svg)

**Related Topics**
[rates](/topic/rates)
[sanofi](/topic/sanofi)
[stocks healthcare](/topic/stocks-healthcare)
[$bpmc](/topic/$bpmc)

[Post Link](https://x.com/MoHossain/status/1930084774389186905)